David Julian Sermer, M.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Lymphoma, Large B-Cell, Diffuse | 5 | 2022 | 1303 | 1.500 |
Why?
|
| Antigens, CD19 | 3 | 2022 | 348 | 1.010 |
Why?
|
| Receptors, Antigen, T-Cell | 2 | 2022 | 2497 | 0.860 |
Why?
|
| Waldenstrom Macroglobulinemia | 2 | 2022 | 1001 | 0.590 |
Why?
|
| Immunotherapy, Adoptive | 2 | 2022 | 1031 | 0.540 |
Why?
|
| Proto-Oncogene Proteins c-myc | 1 | 2020 | 997 | 0.530 |
Why?
|
| Lymphoma | 1 | 2019 | 1889 | 0.390 |
Why?
|
| Mandibulofacial Dysostosis | 1 | 2007 | 39 | 0.340 |
Why?
|
| T-Lymphocytes | 3 | 2022 | 10380 | 0.330 |
Why?
|
| Limb Deformities, Congenital | 1 | 2007 | 132 | 0.310 |
Why?
|
| Epigenesis, Genetic | 1 | 2019 | 3458 | 0.290 |
Why?
|
| Prenatal Diagnosis | 1 | 2007 | 1162 | 0.200 |
Why?
|
| Abnormalities, Multiple | 1 | 2007 | 1385 | 0.190 |
Why?
|
| Proto-Oncogene Proteins c-bcl-6 | 1 | 2020 | 202 | 0.190 |
Why?
|
| Myeloid Differentiation Factor 88 | 1 | 2022 | 557 | 0.170 |
Why?
|
| Antineoplastic Agents | 1 | 2019 | 13731 | 0.150 |
Why?
|
| Lymphoma, B-Cell | 1 | 2022 | 931 | 0.140 |
Why?
|
| Methotrexate | 1 | 2021 | 1723 | 0.130 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 1 | 2020 | 1388 | 0.120 |
Why?
|
| Genetic Engineering | 1 | 2019 | 956 | 0.120 |
Why?
|
| Central Nervous System Neoplasms | 1 | 2021 | 870 | 0.120 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 3 | 2021 | 11317 | 0.100 |
Why?
|
| Antigens, Neoplasm | 1 | 2019 | 2003 | 0.100 |
Why?
|
| Anticarcinogenic Agents | 1 | 2012 | 261 | 0.100 |
Why?
|
| Research | 1 | 2019 | 2018 | 0.100 |
Why?
|
| B-Lymphocytes | 1 | 2022 | 4919 | 0.090 |
Why?
|
| Protein Kinase Inhibitors | 2 | 2022 | 5482 | 0.090 |
Why?
|
| Retrospective Studies | 4 | 2021 | 72253 | 0.070 |
Why?
|
| Humans | 11 | 2022 | 715118 | 0.070 |
Why?
|
| Drug Approval | 1 | 2012 | 871 | 0.070 |
Why?
|
| Drug Discovery | 1 | 2012 | 1067 | 0.060 |
Why?
|
| Autopsy | 1 | 2007 | 990 | 0.060 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2022 | 8925 | 0.060 |
Why?
|
| Clinical Trials as Topic | 1 | 2019 | 8016 | 0.060 |
Why?
|
| Face | 1 | 2007 | 983 | 0.050 |
Why?
|
| Syndrome | 1 | 2007 | 3195 | 0.050 |
Why?
|
| Injections, Spinal | 1 | 2021 | 316 | 0.050 |
Why?
|
| Prospective Studies | 2 | 2022 | 51182 | 0.050 |
Why?
|
| Vincristine | 1 | 2021 | 1040 | 0.040 |
Why?
|
| Neoplasms | 2 | 2019 | 20515 | 0.040 |
Why?
|
| Mutation | 1 | 2022 | 29441 | 0.040 |
Why?
|
| Bone and Bones | 1 | 2007 | 2566 | 0.040 |
Why?
|
| Prednisone | 1 | 2021 | 1549 | 0.040 |
Why?
|
| Treatment Outcome | 2 | 2021 | 62186 | 0.040 |
Why?
|
| Cyclophosphamide | 1 | 2021 | 2189 | 0.030 |
Why?
|
| Doxorubicin | 1 | 2021 | 2233 | 0.030 |
Why?
|
| Piperidines | 1 | 2022 | 1598 | 0.030 |
Why?
|
| Pyrazoles | 1 | 2022 | 1974 | 0.030 |
Why?
|
| Disease-Free Survival | 1 | 2021 | 7051 | 0.020 |
Why?
|
| Pyrimidines | 1 | 2022 | 2969 | 0.020 |
Why?
|
| Recurrence | 1 | 2021 | 8269 | 0.020 |
Why?
|
| Infant, Newborn | 1 | 2007 | 24645 | 0.020 |
Why?
|
| Animals | 1 | 2019 | 170733 | 0.020 |
Why?
|
| Aged, 80 and over | 2 | 2021 | 58503 | 0.020 |
Why?
|
| United States Food and Drug Administration | 1 | 2012 | 1745 | 0.020 |
Why?
|
| Adult | 3 | 2022 | 212128 | 0.010 |
Why?
|
| Male | 3 | 2021 | 351080 | 0.010 |
Why?
|
| Follow-Up Studies | 1 | 2021 | 39285 | 0.010 |
Why?
|
| Aged | 2 | 2021 | 162672 | 0.010 |
Why?
|
| Middle Aged | 2 | 2021 | 214868 | 0.010 |
Why?
|
| Risk Factors | 1 | 2021 | 70705 | 0.010 |
Why?
|
| Young Adult | 1 | 2021 | 56155 | 0.010 |
Why?
|
| Female | 2 | 2021 | 377328 | 0.010 |
Why?
|
| United States | 1 | 2012 | 67666 | 0.000 |
Why?
|